MARKET

ARAV

ARAV

Aravive Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.16
+0.33
+5.66%
Closed 16:00 04/08 EDT
OPEN
6.23
PREV CLOSE
5.83
HIGH
6.24
LOW
5.74
VOLUME
97.28K
TURNOVER
--
52 WEEK HIGH
15.62
52 WEEK LOW
3.340
MARKET CAP
92.50M
P/E (TTM)
-3.9057
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ARAV stock price target is 26.00 with a high estimate of 31.00 and a low estimate of 15.00.

EPS

ARAV News

More
  • Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
  • GlobeNewswire · 03/30 13:00
  • We're Not Very Worried About Aravive's (NASDAQ:ARAV) Cash Burn Rate
  • Simply Wall St. · 03/30 11:17
  • Aravive Reports Fourth Quarter and Twelve Months Ended December 31, 2019 Financial Results and Provides Recent Corporate Updates
  • GlobeNewswire · 03/27 13:00
  • Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
  • GlobeNewswire · 03/24 13:00

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About ARAV

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
More

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.